A Natural Compound Methylnissolin: Physicochemical Properties, Pharmacological Activities, Pharmacokinetics and Resource Development
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s518508 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Ziyang Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Isoflavones, Biological Products, Antineoplastic Agents, Phytogenic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Methylnissolin (also known as Astrapterocarpan) is an isoflavonoid compound featuring a pterocarpan core structure. To date, leguminous plants of the genus Astragalus remain the exclusive natural source of Methylnissolin and its glycoside derivative, Methylnissolin-3-O-glucoside. Upon oral administration, Methylnissolin and its glycosides enter systemic circulation and modulate signaling pathways such as RIPK2/ASK1, PI3K/AKT, IκB/NF-κB, MAPK, and Nrf2/HO-1. Their pharmacological activities span anti-inflammatory, antioxidant, glucose-lipid metabolism regulation, and antitumor effects, underscoring their broad potential for drug development. This review comprehensively evaluates the physicochemical properties, pharmacological activities, mechanisms of action, pharmacokinetic characteristics, and toxicological profile of Methylnissolin and its glycoside derivatives. Notably, we systematically elucidate the metabolic fate of methylnissolin, identifying hydroxylation, demethylation, dimerization, hydration, and dehydrogenation as predominant biotransformation pathways. Furthermore, the influence of factors such as plant variety, geographical origin, and processing methods on Methylnissolin and its glycoside content in Astragalus membranaceus is analyzed, providing crucial insights for drug development and resource utilization. Keywords: methylnissolin, methylnissolin-3-O-glucoside, astrapterocarpan, astragalus mongholicus, pharmacokinetics, pharmacological activity
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
- Guangdong Nephrotic Drug Engineering Technology Research Center, Guangdong Consun Pharmaceutical Group, Guangzhou, People's Republic of China.
- State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
- Guangzhou Key Laboratory of Chirality Research on Active Components of Traditional Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, People's Republic of China.
- Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China.
ORCID-Profile: Ziyang Lin, Bo Liu
Zitieren
APA
Lin, Z., Liang, M., Zhang, X., Cen, Z., Kang, F., Liang, B., Lai, Y., Li, M., Duan, T., Yang, J., & Liu, B. (2025). A Natural Compound Methylnissolin: Physicochemical Properties, Pharmacological Activities, Pharmacokinetics and Resource Development. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s518508
Vancouver
Lin Z, Liang M, Zhang X, Cen Z, Kang F, Liang B, et al. A Natural Compound Methylnissolin: Physicochemical Properties, Pharmacological Activities, Pharmacokinetics and Resource Development. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s518508
BibTeX
@article{Lin2025,
author = {Lin, Ziyang and Liang, Mingjie and Zhang, Xianlong and Cen, Zhuo and Kang, Fengxin and Liang, Baien and Lai, Ying and Li, Minyi and Duan, Tingting and Yang, Junzheng and Liu, Bo},
title = {A Natural Compound Methylnissolin: Physicochemical Properties, Pharmacological Activities, Pharmacokinetics and Resource Development},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s518508}
}
EUVIMED